Briggs Morrison - 17 Sep 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Issuer symbol
SNDX
Transactions as of
17 Sep 2021
Net transactions value
-$904,771
Form type
4
Filing time
21 Sep 2021, 16:35:03 UTC
Previous filing
10 Jun 2021
Next filing
20 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $505,886 +70,262 +145% $7.20 118,598 17 Sep 2021 Direct
transaction SNDX Common Stock Sale $1,410,018 -70,262 -59% $20.07 48,336 17 Sep 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $360 +50 +0.1% $7.20 48,386 20 Sep 2021 Direct
transaction SNDX Common Stock Sale $1,000 -50 -0.1% $20.00 48,336 20 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -70,262 -100% $0.000000* 0 17 Sep 2021 Common Stock 70,262 $7.20 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -50 -100% $0.000000* 0 20 Sep 2021 Common Stock 50 $7.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The sale prices ranged from $20.00 to $20.32.
F3 This option is fully vested.